Search PubMed⌕ Search

Biomedical subjects

R L Goode

Publications and source records attributed to R L Goode.

At least 55 records · Page 3Linked to original sources
PubMed1995

Sound pressure gain produced by the human middle ear.

The acoustic function of the middle ear is to match sound passing from the low impedance of air to the high impedance of cochlear fluid. Little information is available on the actual middle ear pressure gain in human beings. This article describes experiments on middle ear pressure gain in six fresh human temporal bones. Stapes footplate displacement and phase were measured with a laser Doppler vibrometer before and after removal of the tympanic membrane, malleus, and incus. Acoustic insulation of the round window with clay was performed. Umbo displacement was also measured before tympanic membrane removal to assess baseline tympanic membrane function. The middle ear has its major gain in the lower frequencies, with a peak near 0.9 kHz. The mean gain was 23.0 dB below 1.0 kHz, the resonant frequency of the middle ear; the mean peak gain was 26.6 dB. Above 1.0 kHz, the second pressure gain decreased at a rate of -8.6 dB/octave, with a mean gain of 6.5 dB at 4.0 kHz. Only a small amount of gain was present above 7.0 kHz. Significant individual differences in pressure gain were found between ears that appeared related to variations in tympanic membrane function and not to variations in cochlear impedance.

Acoustic Stimulation↗
PubMed1995

The TMJ-ear connection.

This article documents the existence of three structures that traverse through the petrotympanic fissure. These structures are the mandibular malleolar ligament, the chorda tympani nerve and the anterior tympanic artery. The mandibular malleolar ligament or the disk-malleolar ligament originates on the anterior process of the mallous. It traverses through the petro-tympanic fissure and attaches to the posterior portion of the capsule and disk of the temporomandibular joint. The chorda tympani nerve supplies sensory feeling to the posterior two thirds of the tongue. The anterior tympanic artery supplies blood to the area of the tympanic membrane. Clinical experience with implants that impinge or cover ear problems and other symptoms. Removal of these implants and placements with devices that do not cover these structures often relieve these symptoms.

Arteries↗
PubMed1995

Measurements of the stapes superstructure.

Ten human stapes from fresh temporal bones were measured to obtain relevant distances of the stapes superstructure. The dimensions of the parts of the superstructure are as follows: 1) stapes head 1.14 mm (range, 0.91 to 1.49) in diameter parallel to the axis of the footplate and 0.83 mm (range, 0.65 to 1.08) perpendicular to it; 2) stapes head to shoulders 0.93 mm (range, 0.81 to 1.07), head to foramen 1.26 mm (range, 1.15 to 1.39), and head to lateral surface of stapes footplate 3.19 mm (range, 2.91 to 3.45); 3) neck width parallel to the axis of the footplate 1.18 mm (range, 0.88 to 1.47) and 0.64 mm (range, 0.48 to 0.88) perpendicular to it; 4) anterior crus 0.58 mm wide (range, 0.41 to 0.74) at the shoulder of the arch and 0.51 mm (range, 0.39 to 0.65) closer to the stapes footplate; 5) posterior crus 0.65 mm wide (range, 0.46 to 0.77) at the shoulder of the arch and 0.55 mm (range, 0.38 to 0.75) closer to the stapes footplate; and 6) maximum width of entire superstructure near footplate 2.48 mm (range, 2.06 to 2.98).

Age Factors↗
PubMed1995

Treatment of tympanic membrane retraction with the holmium laser.

Politzerization, the Valsalva maneuver, and ventilation tube insertion are available treatments for tympanic membrane retraction. Ventilation of the middle ear cavity can correct tympanic membrane retraction in many cases, but not in all. Retraction may be localized or diffuse. This article describes experiments performed to evaluate a new method to "tighten" retracted or flaccid tympanic membranes with a holmium laser in a human temporal bone model. Ten temporal bones with mild-to-moderate retraction of the posterior superior quadrant or pars flaccida were treated with a series of laser pulses around and to the area of retraction. Umbo displacement before and after laser treatment was performed with a laser Doppler vibrometer to evaluate the effect on the acoustic function of the tympanic membrane. In all ears, the posterior superior quadrant retraction appeared to be completely corrected. Laser treatment of the posterior superior quadrant retraction produced improvement in umbo displacement below 1.0 kHz. After treatment of pars flaccida retraction, the configuration was improved a small amount; however, no increase in umbo displacement was found.

Acoustics↗
PubMed1995

The history and development of the implantable hearing aid.

Implantable hearing aids have an interesting and colorful history. These devices have usually been investigational, but this has changed. Currently, several implantable devices are available for ongoing clinical trials in humans. They have promise in providing improved hearing in certain cases of conductive, mixed, and sensorineural hearing loss.

Bone Conduction↗
PubMed1995

Current status and future of implantable electromagnetic hearing aids.

Partially implantable electromagnetic hearing aids have several potential advantages over conventional hearing aids. As conventional hearing aids improve in the quality of sound they deliver, however, the role of implant aids must be redefined. One area where they may provide the most benefit is in patients with moderate to severe hearing loss.

Biomedical Engineering↗
PubMed1994

Experimental models of ossiculoplasty.

Measurement of the acoustic properties of middle ear prostheses in an appropriate model prior to insertion in humans should be part of the routine of the prosthesis development and testing process, but it is not. This article describes a human temporal bone model suitable for such testing and discusses the results of several commonly used prostheses evaluated in the model. By comparing existing and new experimental prostheses in such a model, we should be better able to develop prostheses capable of providing improved hearing results following middle ear reconstruction.

Acoustics↗
PubMed1994

New knowledge about the function of the human middle ear: development of an improved analog model.

Conventional teaching regarding the acoustic function of the human middle ear is that it serves as an impedance matching system to offset the loss that occurs when sound passes from the low-impedance sound field to the high-impedance cochlear fluid. A transformer analogy is often used with the pressure transformation produced by the eardrum; footplate area ratio and the lever ratio considered to be approximately 27 dB. Recent data on middle ear function has shown this to be only partially correct. A transformer analogy is not appropriate since the pressure gain of the middle ear decreases above 1000 Hz and does not depend on the cochlear load at all frequencies. Experiments are described of umbo, malleus short process, and stapes displacement in human temporal bones using a laser Doppler measuring system (LDS). The measurements support previous studies that indicate that in addition to a roll-off in tympanic membrane function above 1000 Hz, there is slippage in the ossicular lever system that causes an increasing "lever ratio" above 1000 Hz, thought to be caused by translational movement of the ossicular rotation axis near the short process. An improved analog circuit model of the external and middle ear has been developed that produces results equivalent to those found in the temporal bones.

Acoustic Stimulation↗
PubMed1994

Experimental study of the acoustic properties of incus replacement prostheses in a human temporal bone model.

Many middle ear prostheses are available for reconstruction of a missing or damaged incus. Little is known of the relative acoustic performance of these prostheses in vitro and the parameters (mass, shape, tension, angulation, area of head) that modify this performance. This report describes experiments in a human temporal bone model comparing the effect on stapes displacement of six commercially available incus replacement prostheses (IRP). Measurements were performed using a laser Doppler vibrometer before and after incus removal and IRP placement between the tympanic membrane (TM) and stapes head. In addition, experiments were performed on the effect of increasing prosthesis mass, varying the tension between TM and stapes head, changing the surface area in contact with the TM, and comparing different TM contact sites. All prostheses tested showed reasonable acoustic performance compared to the baseline condition. Optimum tension between the TM and stapes head produced the best overall sound transmission. The mid-malleus and umbo locations were the best malleus contact sites; however, the posterior TM contact site also worked well. Increased mass improved low frequency transmission and impaired higher frequency transmission, whereas a larger contact area with the TM contributed to increased gain in the mid frequencies.

Aged↗
PubMed1993

Pharmacologic and surgical enhancement of composite graft survival.

A previously described rabbit ear model was used to address the following issues: (1) the role of surgical delay in composite tissue transfer, (2) optimal enhancement of graft survival using the corticosteroid methylprednisolone, (3) pharmacologic salvage of the failing composite graft, and (4) efficacy of a nonsteroidal dual cyclooxygenase/lipooxygenase inhibitor (SK&F 86002) in enhancing graft survival. Preoperative and immediate postoperative steroid treatment groups exhibited a significant improvement in graft survival area compared with the untreated control group. Preoperative initiation of steroid therapy was more effective than a strictly postoperative regimen. SK&F 86002, advance preparation of the recipient bed, and delayed steroid administration did not improve graft survival compared with the untreated control group. The most promising treatment, preoperative initiation of steroid therapy, was further evaluated in a double-blinded placebo-controlled study. The steroid group demonstrated a significantly improved mean survival area, as well as mean graft weight, compared with the placebo control group.

Animals↗
PubMed1993

LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male rats.

LY207320 is an in vitro inhibitor (estimated IC50 = 0.06 microM) of steroid 5 alpha-reductase that catalyzes the conversion of testosterone (T) to dihydrotestosterone (DHT). In contrast, LY207320 was only moderately active against rat prostatic 5 alpha-reductase in vivo (32% inhibition at 50.0 mg/kg single dose). LY207320 did, however, inhibit the in vivo uptake of [3H]-T by the prostate. The antiprostatic and endocrine effects of this agent were evaluated following daily (21 days) administration to castrated, androgen-supplemented castrate, and intact rats. LY207320, which has modest progestational competitive binding activity, does not bind to rat prostatic androgen or uterine estrogen cytosolic receptors. In the castrated male rat, subcutaneously (s.c.) administered LY207320 had no androgen agonist activity, as evidenced by a lack of accessory sex organ weight gains. Administration of s.c. LY207320 to intact rats for 21 days at doses greater than 5.0 mg/kg-day produced significant (P < 0.05) reductions of seminal vesicle and ventral prostatic weights (maximal regression = -65% and -40% from control values, respectively at 50.0 mg/kg-day). The compound had no regressive activity on male accessory sex organs when administered orally. LY207320 did not alter circulating prolactin, LH, or corticosterone levels, but at high doses (> or = 50.0 mg/kg-day), lowered circulating T[-67% from intact control levels (P < 0.05)]. Histological analysis of the rat ventral prostates (RVPs) in LY207320-treated rats was consistent with an androgen-deprived state. Decreased circulating androgens and prostatic regression are associated with inhibition of testicular 17 alpha-hydroxy/C17,20-lyase enzyme activity (IC50 = 0.06 microM). These findings support the contention that LY207320 is a physiological antagonist of androgen action in male rats, and that its effects are mediated primarily through inhibition of testicular androgen production rather than accessory sex organ 5 alpha-reductase.

Aldehyde-Lyases↗
PubMed1993

Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat.

The benzothiophene anti-estrogen, raloxifene [LY156758; (6-hydroxy-2-(4-hydroxyphenyl) benzo(b)thien-3-yl)(4-(2-1-piperidinyl)ethoxy)phenyl methanone hydrochloride] has selective estrogen pharmacological antagonist activity in female rats. The present studies were done in the male rat to assess activity of raloxifene related to inhibition of prostatic growth and effects on the hypothalamic-pituitary-gonadal axis. Raloxifene did not compete for binding of the androgen, [3H]-methyltrienolone (R1881) in cytosolic extracts of ventral prostate. Similarly, the compound did not inhibit prostatic 5 alpha-reductase or testicular 17 alpha-hydroxy/C17,20-lyase activities. Raloxifene had no effect on the ventral prostatic uptake of [3H]-R1881 in vivo. Administration of estradiol to castrated male rats stimulated fourfold increases of in vitro ventral prostatic binding of [3H]-R1881. Raloxifene was devoid of agonist activity in castrated animals, because the compound had no stimulatory effect on prostatic androgen receptor binding activity. When raloxifene was coadministered with estradiol, the compound markedly antagonized the estrogen-induced increase of prostatic [3H]-R1881 binding, confirming its antiestrogenic properties in male rats. Serum prolactin was also elevated significantly (P < 0.05) with a single injection of raloxifene (20.0 mg/kg). In these same animals, serum FSH was significantly (P < 0.05) decreased by one dose (10.0 mg/kg) of the compound. Luteinizing hormone levels in castrated male rats were unaffected by raloxifene administration. Raloxifene treatment of castrated males significantly (P < 0.05) antagonized the stimulatory response of the ventral prostate (VP) to exogenous androgens in a dose-dependent manner. Raloxifene treatment of intact male rats for 14 and 28 days produced significant (P < 0.05) dose-dependent regression of the VP and seminal vesicles (SV). The VP regressive responses to raloxifene were associated with a decline in serum testosterone levels. Histological analysis of the VPs in raloxifene-treated rats was consistent with an androgen-deprived state. These findings support the contention that raloxifene is a pure estrogen antagonist and a physiological antagonist of androgen action in male rats. These pharmacological properties provide support for further structure-activity and mechanistic investigations with benzothiophenes in the medical management of prostatic neoplasia.

Aldehyde-Lyases↗
PubMed1993

Effect of changes in mass on middle ear function.

Vibrating systems such as the middle ear are affected by changes in mass. After disease or ear surgery, significant changes in mass may contribute positively or negatively to the postoperative hearing threshold. This article describes experiments in 15 human temporal bones of the addition or reduction of mass on the middle ear transfer function. Measurement of stapes and umbo vibration was performed using a Laser Doppler Vibrometer before and after the addition of different masses at several sites on the tympanic membrane (TM) and ossicular chain. The input was 61 pure tones swept from 147 to 19433 Hz at 80 dB SPL. The addition of mass onto the TM produced varying detrimental effects on sound transmission, depending on the location and amount of mass. The insertion of ventilation tubes, weighing 12 to 17 mg each, produced losses at 1.5 to 5.0 kHz compared with tympanotomy alone. Addition of mass to the umbo and malleus head produced a loss at mid and high frequencies, whereas addition of mass on the incus long process and stapes also produced a high-frequency decrease in stapes displacement. Reduction of TM mass by removal of the epithelium produced an increase, especially at 2.0 to 4.0 kHz.

Adult↗
PubMed1993

Measurement of umbo vibration in human subjects--method and possible clinical applications.

A commercial laser doppler vibrometer (LDV) was used to evaluate umbo displacement at sound pressure levels of 60, 70, and 80 dB SPL at the tympanic membrane (TM) of six subjects. Thirty-five pure-tone test frequencies, five per octave, were tested from 140 to 19,433 Hz. A computer program (Tymptest) produced and controlled the tones as well as improved the signal-to-noise ratio of the LDV. The test took about an hour to perform and provided reproducible results in all subjects. In addition, measurement of umbo displacement using the same system was made in 15 fresh human temporal bones for comparison. Results in the humans revealed a relatively flat umbo displacement from 140 to 1000 Hz, with a gradually sloping roll-off of -8.25 dB per octave from 1000 to 7000 Hz. From 8000 to 14,000 Hz the roll-off increased to -12.5 dB per octave. At the mean resonant frequency of the middle ear, 1000 Hz, and an 80 dB SPL input, umbo displacement was 0.045 micron. The human temporal bones showed similar results. Possible future clinical applications of this measurement include the identification of ears with acoustically inefficient TMs (tin ears). By identifying and studying such ears we should be able to develop methods to improve their function and produce hearing threshold increases of 15 dB or more at key speech frequencies. In addition, analysis of umbo and TM vibration in reconstructed middle ears should help us achieve better postoperative hearing results.

Adolescent↗
PubMed1992

Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.

The effects of hormonal ablation, estrogen, estrogen-derived cytotoxic agent, and estrogen antagonist therapies used clinically were evaluated on in vitro colony formation, in vivo growth, and lymphatic and pulmonary metastasis of the PAIII tumor. Ventral prostatic and seminal vesicle weights were evaluated in the same animals to assess androgen-related responses. Estradiol, estramustine phosphate, and testosterone had no effects on PAIII colony formation in vitro. Castration, hypophysectomy, estradiol benzoate, and estramustine phosphate treatment of PAIII-bearing Lobund Wistar rats produced significant (P less than 0.05) regression of male accessory sex organs. Of these treatments, only hypophysectomy had significant (P less than 0.05) inhibitory effects on primary PAIII growth and lymphatic and pulmonary metastasis. LY117018 [6-hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-2-(l-pyrrolidin yl)ethoxy phenyl ketone] has antiestrogenic activity but produces no significant agonist responses. LY117018 had no effect upon PAIII colony formation in vitro. Following s.c. implantation of PAIII cells, LY117018 (2.0, 10.0, or 20.0 mg/kg s.c.) had no effect on primary tumor growth in the tail. In vitro LY117018 administration produced marked antimetastatic effects. In a dose-dependent manner, LY117018 inhibited PAIII metastasis to the gluteal (97%) and iliac lymph nodes (88%) (P less than 0.05 for both). LY117018 also maximally inhibited pulmonary metastasis by 86% (P less than 0.05). Maximal regression of 42% for ventral prostatic and 35% for seminal vesicle weights were also seen after LY117018 administration (P less than 0.05 for both). Co-administration of estradiol benzoate had no antagonistic effect upon the antitumor responses produced by LY117018. The mechanism of action of LY117018 is not known. The failure of estradiol benzoate to affect PAIII growth and metastasis supports the contention that the responses to LY117018 are not attributable to simple antagonism of estrogen action. LY117018 may be exerting its antitumor effects through autocrine, paracrine, or endocrine mechanisms. LY117018 represents a class of agents with potential utility in treating metastatic cancer of the prostate.

Adenocarcinoma↗